CinCor Pharma to Present at the Jefferies Healthcare Conference
CinCor Pharma announced its participation in the Jefferies 2022 Healthcare Conference, scheduled for June 8-10 in New York.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
CinCor Pharma announced its participation in the Jefferies 2022 Healthcare Conference, scheduled for June 8-10 in New York. The management team will present on June 9 at 9 AM EDT, with a live webcast available online. A replay of the presentation will be archived for 90 days. CinCor, a clinical-stage biopharmaceutical company founded in 2018, focuses on innovative treatments for cardio-renal diseases, with its lead asset, baxdrostat (CIN-107), in development for hypertension and primary aldosteronism.
Details
News Market Reaction – CINC
The recorded move for CINC in the trading session of this news was +10.09%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
WALTHAM, Mass., May 31, 2022 (GLOBE NEWSWIRE) -- CinCor Pharma, Inc. (NASDAQ: CINC) today announced participation at the Jefferies 2022 Healthcare Conference taking place June 8 - 10 in New York, New York. The CinCor management team will give a corporate presentation on June 9, 2022, at 9 AM EDT.
A link to the live webcast is available at webcast/jefferies. An archived replay of the presentation will be available for 90 days at CinCor.com/events.
The CinCor management team will also participate in one-on-one investor meetings during the event. Investors interested in meeting with CinCor at the conference should contact their Jefferies representative.
About CinCor
CinCor, founded in 2018, is a clinical-stage biopharmaceutical company with a mission to bring innovation to the pharmaceutical treatment of cardio-renal diseases. Its lead asset, baxdrostat (CIN-107), a highly selective, oral small molecule inhibitor of aldosterone synthase, is in clinical development for the treatment of hypertension and primary aldosteronism.
About Baxdrostat (CIN-107)
Baxdrostat (CIN-107) is a highly selective, oral small molecule inhibitor of aldosterone synthase, the enzyme responsible for the synthesis of aldosterone in the adrenal gland, in development for patient populations with significant unmet medical needs, including treatment-resistant hypertension and primary aldosteronism. Hypertension, which is defined by the American College of Cardiology and the American Heart Association as resting blood pressure above 130/80 mm Hg, is generally acknowledged to be one of the most common preventable risk factors for premature death worldwide. Though often asymptomatic, hypertension significantly increases the risk of heart disease, stroke and kidney disease, amongst other diseases. It is estimated that as much as
| Contacts: | Investors: |
| Terry Coelho | Bob Yedid |
| CinCor Pharma, Inc. | LifeSci Advisors |
| EVP, CFO and CBDO | ir@CinCor.com |
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.